Table 2.
Glioma cell-line xenograft (CLX) and syngeneic murine models.
Mouse Species | Brain Tumor Modeled | Tumor Cell Line | Reference |
---|---|---|---|
BALB/c OlaHsd-Foxn1nu | Glioma | BT3 cells | [29] |
C57BL6/N | High Grade Glioma | GL261 cells | [30,31,32,33,34,35,36,37] |
High Grade Glioma | U87 and GL261 cells | [38] | |
CBA, BALB/c, AKR, C57 black, and RIII | Glioma | Rat C6 cells | [27] |
CD-1, Nude, and NOD CRISPR Prkdc IL2Rγnull | Glioma | DAOY and T98G cells | [39] |
CIEA-NOG | Glioblastoma (GBM) | Patient derived glioma cell lines | [40] |
C6B3F1 | High Grade Glioma | Mouse Tu2449, Tu9648 and Tu251 mouse glioma cell lines | [41] |
Foxn1nu/nu | Glioma | BT4C cells | [29,42] |
ICR | High Grade Glioma | C6 rat glioma cells | [43] |
Non-obese/diabetic (NOD)/Severe combined immunodeficient (SCID) | Isocitrate dehydrogenase 1 (IDH1) Mutated Glioma | Patient derived IDH1 mutant oligoastrocytoma | [44] |
GBM | TG1 human GBM cell line | [45] | |
GBM | T98 and U87 glioma cell lines | [46] | |
Nude/NOD/SCID | High Grade Glioma | U87, U118, LN18, LN229 cell lines | [47] |
Not reported | GBM | U87 and U373 glioma cell lines | [48] |
Nude | GBM | Ink4a/ARF−/− Id4 astrocyte cells | [49] |
Malignant Astrocytoma | Commercial malignant cell lines | [50] | |
High Grade Glioma | BT70 malignant glioma cell line | [51] | |
High Grade Glioma | U87 human glioma cell line and C6 rat glioma cell line | [52] | |
GBM | LN229 and U87 human glioma cells | [53] | |
High Grade Glioma | E98 and E473 glioma cell lines | [54] | |
GBM | Mouse GL261 cell line | [55] | |
GBM | Human U87 glioma and rat 9L glio-sarcoma cell lines | [56] | |
GBM | Patient derived GBM cell lines | [57,58,59] | |
High Grade Glioma | Human astroglioma U373 and T98G and oligodendroglioma Hs683 cell lines | [60] | |
High Grade Glioma | Human glioma U87, U251, U373, A172, LN18, LN229, and D54 cell lines | [61] | |
High Grade Glioma | Hs683 cells | [62] | |
High Grade Glioma | LN229 cells | [63,64] | |
High Grade Glioma | SHG44 cells | [65] | |
High Grade Glioma | T98G and U373 cells | [66] | |
High Grade Glioma | U87, U251 and D566 cells | [67] | |
High Grade Glioma | U87 cells | [68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90] | |
GBM | U87. LNZ308, LN229 cells | [91] | |
High Grade Glioma | U87, U118, N10, U251, A172, and U373 cell lines | [92] | |
High Grade Glioma | U251 cell line | [93,94] | |
GBM | U87 and LN229 cell lines | [95] | |
GBM | LN229 cell line | [96] | |
Glioma | E102 and E106 glioma cell lines | [97] | |
Glioma | SNB-19 U87 glioma cell lines with co-transfecting COS-7 cells with pTet-On and treated with doxycycline | [98] | |
High Grade Glioma | Human T269 4IgB7H3 knockdown or control cells (orthotopic); LN-229 4IgB7H3 knockdown or control cells (subcutaneous) | [99] | |
High Grade Glioma | U87 and U251 glioma cell lines | [100] | |
Glioma | A-172, U343, U87 and T98G glioma cells | [101] | |
Glioma | U87 glioma cell line | [102] | |
Glioma | U373 human glioma cell line | [103] | |
SCID | High Grade Glioma | GLI36-EGFRvIII engineered cells | [104] |
Glioma | Patient-derived GSC lines | [105,106,107] |